SCHEMBL5440752

SCHEMBL5440752

CSC(=Nc1ccc(Cl)cc1)N1CCC(Nc2ncccn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.47
IKBKB O14920 3/20 0.43
MAPK8 P45983 1/20 0.38
KCNH2 Q12809 1/20 0.38
NOS2 P35228 5/20 0.38
NOS1 P29475 4/20 0.38
NOS3 P29474 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ACHE P22303 1/20 0.37
BACE1 P56817 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5440749 1.00 EPHX2 (0.47) EPHX2IKBKBMAPK8KCNH2NOS2
SCHEMBL5434480 0.80 EPHX2 (0.46) EPHX2NOS2NOS1NOS3ALDH1A1
SCHEMBL5434476 0.80 EPHX2 (0.46) EPHX2NOS2NOS1NOS3ALDH1A1
SCHEMBL4885177 0.78 NOS3 (0.45) NOS2NOS1NOS3ALDH1A1MAPT
SCHEMBL14066257 0.78 NOS3 (0.45) NOS2NOS1NOS3ALDH1A1MAPT
SCHEMBL4885189 0.78 NOS3 (0.45) NOS2NOS1NOS3ALDH1A1MAPT
SCHEMBL5427966 0.77 EPHX2 (0.45) EPHX2KCNH2
SCHEMBL5427969 0.77 EPHX2 (0.45) EPHX2KCNH2
SCHEMBL5424945 0.76 JAK2 (0.38) KCNH2NOS2NOS1NOS3ALDH1A1
SCHEMBL5424947 0.76 JAK2 (0.38) KCNH2NOS2NOS1NOS3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225333-A1 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor BRYANS JUSTIN S 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225333-A1 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor AVPR2, RXFP3, AVPR1A EPHX2 1357/4885IKBKB 2026/4885MAPK8 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.